WIP + Publication Round Up
George Gifford
WIN Wednesday
Wednesday, 23 October 2024, 12pm to 1pm
Hybrid via Teams and in the Cowey Room, WIN Annexe
Join via TeamsSTEP-ENHANCE - AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial
Presented by George Gifford
Abstract: Despite the fact that antipsychotics are effective in most people with schizophrenia, about a third of patients respond poorly. There is evidence that non-response to antipsychotic treatment may be associated with neurobiological alterations other than D2 dysregulation, suggesting non-dopaminergic pharmacological treatments may be helpful. The first trials investigating the effects of cannabidiol (CBD) on psychotic symptoms in schizophrenia have reported positive results, however these studies investigated chronic psychosis. STEP-ENHACE is a multisite prospective randomised control trials of CBD in a cohort of First Episode Psychosis participants. The study aims to investigate whether the response to antipsychotic treatment can be enhanced by adding cannabidiol (CBD)to the existing treatment, compared to placebo, in participants with a first episode of psychosis, who have had a suboptimal or no response to their first antipsychotic treatment. Participants will be administered MRI at baseline and follow up, including structural MRI, resting state fMRI, MRS, and neuromelanin sensitive MRI.
Title and abstract TBC